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Abstract
Changes in intestinal permeability have been determined to influence secondary 
inflammatory reactions and clinical manifestations such as spontaneous bacterial 
peritonitis (SBP) secondary to cirrhosis. As of yet, no in-depth exploration of the 
changes in the microbiota and how this influences cirrhosis to differ from clinically 
more severe cases than others has not begun. However, at the level of pathophysio-
logical mechanism, it must be taken into account that due to the abuse of substances 
such as alcohol and chronic fatty liver disease, changes in the bacterial composition 
and intestinal permeability are induced. This set of changes in the bacterial com-
position (microbiome) and modification of the intestinal permeability could be 
related to the presence of ascites and spontaneous peritonitis secondary to cirrhosis, 
being of relevance the knowledge of the mechanisms underlying this phenomenon, 
as well as clinical manifestation. Prophylaxis and antibiotic treatment of SBP 
requires clinical knowledge for the treatment decisions based mainly on the pres-
ence of ascitic fluid, accompanied of risk factors, laboratory indexes such as PMN 
count and culture results, in order to determine the kind of molecule that will help 
to the SBP recovery or to amelioration symptoms, always taking care of not exceed 
the antibiotic consumption and restoring the microbiome imbalance.
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1. Introduction
In cirrhotic patients with ascites, spontaneous bacterial peritonitis (SBP), an 
ominous complication, occurs recurrently with an annual increase rate of 69% [1]. 
Furthermore, in cirrhosis with portal hypertension, SBP is a key hallmark feature in 
developing hepatic encephalopathy, variceal bleeding, hepatorenal syndrome and 
increased mortality [2]. Also, intestinal barrier dysfunction is pondered central in 
the pathogenesis of cirrhotic complications. In health, intestinal barrier function is 
Update on Hepatitis C
2
crucial against extensive and continuous exposure of the liver to the gut microbiota 
and their products and metabolites. Thus, gut microbiome sets the stage for the gut-
liver axis [3]. Nevertheless, in cirrhosis, intestinal barrier dysfunction, increased 
permeability and extensive inflammation occurs due to SBP. The intestinal barrier 
consists of several layers, including mucus layer, intestinal epithelial cells, lamina 
propria and Peyer’s patches. They determine the extent to which gut microbes and 
their products (endotoxin) can access the host vasculature [4].
Therefore, the intestinal vascular barrier is considered an important layer 
controlling the entry of gut bacterial products into the portal circulation and liver 
[5]. Gut microbiota may therefore have a prime role in a pathologic loop, which 
regulates portal hypertension, and thus have a role in the cirrhosis development.
SBP is a frequent and severe complication in cirrhotic patients with ascites. On 
the other hand, cirrhotic complication initiates dysregulation of intestinal AMP and 
bacterial overgrowth, which triggers mucosal inflammation. The proinflammatory 
cytokine milieu in the intestinal lumen plays a critical role in disrupting the tight 
junction protein integrity, leading to BT. Bacterial endotoxin and harmful patho-
genic bacterial species translocate to the liver through portal vein further exacerbate 
the already prevalent hepatic inflammation and fibrosis in the liver, causing a cyclic 
progression of liver injury. Pathogenic bacteria and endotoxins also translocate to 
blood causes systemic inflammatory responses induced by cytokines, chemokines 
and interferons resulting cytokine storm syndrome and hemodynamic abnormali-
ties, thereby promotes liver injury followed by multiorgan failure and eventually it 
causes death.
2.  The pathophysiological mechanism involved in spontaneous bacterial 
peritonitis in cirrhosis: loss of permeability and gut microbiota
Peritonitis occurs in patients with cirrhosis and ascites, in the absence of any 
other intra-abdominal cause of infection, such as an abscess or intestinal perfora-
tion. The spontaneous bacterial peritonitis (SBP) is defined as an infection of the 
ascites fluid, which produces an inflammatory reaction of the peritoneum and as 
previously described. It has been associated with intestinal dysbiosis, since it leads 
to dysfunction of the intestinal barrier that can cause bacterial translocation of very 
small quantities of viable or dead bacteria, constituting a physiologically important 
reinforcement for the immune system. Bacterial translocation is defined as the 
passage of bacteria or bacterial products that go from the intestine to the mesenteric 
lymph nodes.
2.1 Bacterial translocation
Due to the close anatomical and physiological connections between the liver 
and gut, barrier dysfunction results in translocation of viable bacteria and its 
product to the liver via the portal circulation, thereby causing liver dysfunction. 
Several experimental studies showed that cirrhotic patients had increased intestinal 
permeability which might be a critical contributing factor to cirrhosis development 
[6, 7]. In addition, microbial overgrowth has been observed in intrahepatic chole-
static patients [8]. Bacterial infections such as SBP and bacteraemia are associated 
with the four-fold increased death rate in cirrhotic patients [9]. In this context, it 
was observed that the presence of bacterial DNA in the blood and ascitic fluid of 
cirrhotic patients developed poor prognosis compared to cirrhotic patients who had 
negative for bacterial DNA [10]. Bacterial translocation (BT) initiates a cycle of 
dysfunctional immune activation, and systemic inflammatory response, facilitating 
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the worsening of pre-existing hepatic and hemodynamic abnormalities in cir-
rhosis [11]. Identification of bacterial DNA has been associated with worsening of 
intrahepatic endothelial dysfunction and extra-hepatic (peripheral) vasodilation 
[12]. Further, lipopolysaccharide-binding protein (LBP) is a surrogate marker for 
BT, correlated with systemic hemodynamic abnormalities in cirrhotic patients 
[13]. Endotoxemia has been closely associated with hyperdynamic circulation, 
coagulopathy, portal hypertension, renal and cardiac dysfunction in cirrhosis [14]. 
Furthermore, systemic inflammatory response syndrome (SIRS) with bacterial 
infection shows an increased risk of 67% in cirrhotic patients suggesting that SIRS 
also contributing to cirrhosis prognosis. Figure 1 [15].
2.2 Gut dysbiosis
Bacterial dysbiosis is characterized by the pathogenic shift in quantity or 
quality from the symbiotic state existing between the host and indigenous bacteria 
[16, 17]. A marked alteration has been observed in the small intestinal microbiota 
in patients with cirrhosis compared to normal individuals. A ratio of autoch-
thonous to non-autochthonous bacterial taxa is referred to as cirrhosis dysbiosis 
ratio (CDR). Patients with cirrhosis were shown to exhibit a lower CDR [16]. The 
pathogenic shift in the proportion of bacterial taxa is also associated with decom-
pensation of cirrhosis. The disruption of microbial balance in cirrhosis leads to 
accumulation of harmful bacterial metabolites that damage the intestinal epithelial 
barrier [16]. Gut dysbiosis also leads to intestinal immune system dysregulation 
by changing the composition of short-chain fatty acids produced by the micro-
biota [17]. This immune dysregulation with functional proinflammatory switch 
Figure 1. 
The pathophysiological mechanism associated with BT and SBP in decompensated cirrhosis. SBP is a frequent 
and severe complication in cirrhotic patients with ascites. On the other hand, cirrhotic complication initiates 
dysregulation of intestinal AMP and bacterial overgrowth, which triggers mucosal inflammation. The 
proinflammatory cytokine milieu in the intestinal lumen plays a critical role in disrupting the tight junction 
protein integrity, leading to BT. Bacterial endotoxin and harmful pathogenic bacterial species translocate to 
the liver through portal vein further exacerbate the already prevalent hepatic inflammation and fibrosis in the 
liver, causing a cyclic progression of liver injury. Pathogenic bacteria and endotoxins also translocate to blood 
causes systemic inflammatory responses induced by cytokines, chemokines and interferons resulting cytokine 
storm syndrome and hemodynamic abnormalities, thereby promotes liver injury followed by multiorgan 
failure and eventually it causes death. Note: AMP-anti microbial peptides; BT-bacterial translocation; IFN-
Interferon; IL-interleukin; IJP-tight junction protein; SBP-spontaneous bacterial peritonitis; TLR-toll-like 
receptor; TNF-tumor necrosis factor.
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contributes to mucosal barrier dysfunction and BT [17] and thus, bile acids (BA) 
derangement, which plays a causal role in the gut dysbiosis.
In cirrhotic patients, intraluminal BA reduction was shown to increase decon-
jugation by enteric bacteria [18]. Moreover, defect in intestinal BA concentration 
accelerates BT and develops susceptibility to bacterial endotoxin [19]. Intestinal 
dysmotility is another important contributor to the development of SBP in cirrhotic 
patients [20].
2.3 Tight junctions and intestinal permeability
Increased intestinal permeability exerts a pivotal role in the pathogenesis of 
SBP in cirrhosis following elevated systemic endotoxemia. Moreover, a significant 
association was found between elevated portal pressure and gastro-duodenal and 
intestinal permeability in cirrhosis [21]. Specific ultrastructural and functional 
alterations in the intestinal mucosa have been identified in cirrhosis patients 
associated with increased intestinal permeability to BT [22]. The intestinal barrier 
comprises tight junction (TJ) proteins that allow specific passage of gut bacterial 
products and metabolites, thus maintaining intestinal structural integrity and 
regulating intestinal permeability following SBP [23]. Zona occludens (ZO-1), 
occludin and claudins are the major integral transmembrane proteins composed 
of TJ and maintaining the intestinal permeability [24]. The TJ proteins expression 
and turnover are predisposed by oxidative stress and inflammation following SBP 
in cirrhosis, consequently, disruption of the intestinal barrier allows bacterial 
endotoxin from the intestinal lumen to pass into the portal circulation and thus 
reaches the liver culminating hepatic complications (Figure 1). Significant altera-
tions in occludin were observed in intestine of both compensated decompensated 
cirrhotic patients compared to healthy subjects [6, 7]. Notably, the reduction in 
intestinal occludin expression was associated with elevated endotoxins levels and 
severe variceal bleeding [6]. We found significantly decreased hepatic ZO 1 levels in 
patients with cirrhosis and HCC [25]. Furthermore, our rodent experimental data 
show evidence that in cirrhosis and HCC, diminished hepatic expression of ZO-1 
and occludin was correlated with BT [25, 26].
2.4 Small intestinal bacterial overgrowth (SIBO)
Small intestinal bacterial overgrowth (SIBO) induced by prolonged gastric 
and small intestinal transit of bacterial products and metabolites. It is a condition 
in which colonic bacterial translocate into the small intestine [27]. The process of 
bacterial dysbiosis, coupled with SIBO, is well documented in cirrhosis [16, 28]. 
Increased proportion of the gram-negative Bacteroides species and the gram-
positive Enterococcus spp. were identified in the small intestine of patients with 
alcoholic liver disease [28]. SIBO is also accompanied by a decrease in Lactobacillus 
spp., which is regarded as beneficial to the host [29]. SIBO coupled with bacterial 
dysbiosis (Figure 1) leads to accumulation of bacterial endotoxins such as LPS, an 
specific PAMP (Pathogen Associated Molecular Patterns), which in turn results in 
the induction of inflammatory response culminating in intestinal epithelial damage 
and gut permeability [30] this mechanism will be explained deeply ahead in this 
chapter. Cirrhotic patients who use proton pump inhibitors are vulnerable to SBP, 
due to intestinal overgrowth of Enterococcus spp. [31, 32]. Antimicrobial peptides 
(AMP) are considered the first line of defence to counter bacterial overgrowth and 
maintain bacterial symbiosis, which are primarily produced by paneth cells and 
intestinal epithelial cells [33]. Decreased AMP was pronounced in the ileum, which 
was associated with increased BT in cirrhosis [34]. Also, human and experimental 
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ALD attributed to decreased AMP expression [33, 35]. Regenerating family member 
3 alpha [Reg3A] belongs to the C-type lectin family is one of the important AMP in 
regulating intestinal inflammation [36] and facilitating the repair of gut mucosa 
in rodent models. Moreover, our recent study shows that Reg3A protein expression 
was significantly reduced in cirrhotic mice small intestine [37]. We also found 
significantly decreased Lactobacillus and increased Bacteroides and Enterococcus 
16 s rRNA levels in the liver and small intestine of cirrhotic mice [37]. This reduced 
intestinal Reg3A expression was associated with an increased Enterococcus trans-
location to rodent cirrhotic liver. Similarly, Darnaud et al., observed that Reg3A 
overexpression in colitis mice attenuated intestinal inflammation and restricted 
BT [36]. Moreover, Reg3A expression protected against dextran sulphate sodium 
(DSS)-induced intestinal inflammation, intestinal permeability and BT in mice 
[36]. In addition, intestinal Reg3A has been reported to promote the enrichments 
of Lactobacilli sp [38] and depletion of Bacteroidetes population [36], indicating 
Reg3A could be a critical factor in restricting BT by averting bacterial dysbiosis. 
Cathelin-related antimicrobial peptide (CRAMP) is an AMP produced by intestinal 
epithelial cells exhibits potent antibiotic activity against various strains of gram-
negative bacteria [39]. Deficiency of CRAMP expression correlated with impaired 
microbial clearance and elevated proinflammatory cytokine response in glial cells 
exposed to bacterial endotoxins [40]. We found CRAMP cellular expression in the 
small intestine of cirrhotic mice albeit, no significant difference between control 
and cirrhotic mice [37].
2.5 Inflammation in spontaneous bacterial peritonitis
Inflammation and oxidative stress are other key players contributing to mucosal 
damage and cirrhosis progression by triggering cytokine productions. Activation 
of Kupffer cells and the recruitment of proinflammatory monocyte subsets could 
propagate both intra-hepatic and extra-hepatic (systemic) inflammation [41, 42]. 
Of note, the cirrhotic patients with bacterial infections exhibited elevated systemic 
levels of inflammatory and pyrogenic cytokines IL-6 and TNF-α compared to 
septicemia patients without cirrhosis [43]. IL-6 levels in cirrhotic patients corre-
lated with immune cell activation, organ failure, and portal hypertension [14, 44]. 
Moreover, soluble TNF-α receptor levels in hepatic venous and portal venous blood 
correlated with endotoxin concentration as well as hemodynamic derangements 
in cirrhosis [45]. Hence endotoxin-induced proinflammatory cytokines serve as 
important mediators of SIRS induced-hemodynamic abnormalities in cirrhosis. 
In this context, our experimental data show evidence that significantly elevated 
ascitic fluid cytokine concentrations in cirrhotic mice [37]. Gastrointestinal tract 
inflammation was contemplated as a major mediator of TJ disruption. Decreased TJ 
proteins ZO-1 and occludin were reported in gastric carcinoma with inflammation 
[46]. In cirrhosis with SBP, intestinal barrier disruption has been precipitated by 
inflammation [26]. Proinflammatory cytokines such as TNF alpha, IL-I beta and 
IFN gamma trigger barrier damage on the gut epithelium by inducing endocytosis 
of TJ proteins and increased expression of myosin light chain kinase protein, 
thereby causing TJ permeability [17, 26]. Intestinal mucosa covered by the mucus 
layer provides a first line of defence mechanism against harmful bacteria and 
endotoxin from invading the microvillus environment [30]. Inflammatory media-
tors, LPS and growth factors affect the secretion of mucin, which is present in the 
mucus layer. In particular, nuclear factor-κB [NF-κB] binds with the specific site 
of the promoter region of mucin and affect its secretion [47]. Therefore, modula-
tion of bacterial adherence to the gut mucosal surface by intestinal mucus results 
in loss of gut barrier function [48]. In this context, a previous experimental study 
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shows evidence in cirrhotic rats ileum that increased mucin 2&3 mRNA expression 
compared to control [49]. Moreover, increased mucus content in the small intestine 
was found following chronic alcohol supplementation to rats [30].
In cirrhosis, SBP is a major precipitating factor initiates gut-liver axis dysfunc-
tion. It is mainly due to the fact that intestinal microbiota dysbiosis, bacterial 
overgrowth and bacterial translocation [4], which originates intestinal mucosal 
dysfunction and damage at the systemic immune cell functions [50]. Moreover, 
inflammation and oxidative stress are other contributing factors that can influence 
the barrier function of both the small and the large intestine and probably result in 
the occurrence of SBP in cirrhosis.
2.6 Microbiota in spontaneous bacterial peritonitis consequence
The gut microbiota plays a key role in spontaneous bacterial peritonitis due 
to intestinal dysbiosis and bacterial translocation. A study conducted by Lachar 
& Bajaj, 2016, demonstrated that patients with spontaneous bacterial peritonitis 
presented intestinal dysbiosis, and thus concluded that it can be a useful quantita-
tive index to describe the microbiome alterations that accompany the progression 
and complications of cirrhosis [51].
The term microbiota refers to the community of living microorganisms that 
reside in a specific ecological niche. In the gastrointestinal tract, the microbiota 
is a dynamic system that maintains a symbiotic relationship with the intestinal 
mucosa. This relationship imparts metabolic, protective and immune functions 
that contribute to the well-being of the host, which are modified by environmen-
tal factors. Additionally, it participates in metabolic processes that connect the 
intestine with liver, muscle and brain [52, 53]. The eubiosis microbiota comprises a 
balance between symbiotic microorganisms [bacteria with homeostasis-promoting 
functions] and pathobionts [commensal bacteria with the ability to induce pathol-
ogy]. However, the dysregulation of this balance can determine a state of dysbiosis 
[54] (Figure 2A). Therefore, alterations in the intestinal microbiota are important 
in the pathogenesis of several complications that arise in liver disease, such as 
spontaneous bacterial peritonitis. This is usually caused by the presence of one or 
more species of aerobic and anaerobic enteric bacteria that act in synergy [55–59] 
(Figure 2B).
The most common microorganisms associated with this disorder are Gram-
negative bacteria, such as Escherichia coli and Klebsiella species, and infections by 
Gram-positive bacteria such as Staphylococcus. Gram negative bacilli, especially 
Escherichia coli, which are found in low concentrations in the small intestine 
of healthy subjects, these are increased as jejunal microbiota in many cirrhotic 
patients, especially in those patients with more advanced cirrhosis and a greater 
decrease in the intestinal motility. Escherichia coli is known to be the main cause 
of SBP and is more frequently isolated in ascites fluid, in previous studies it has 
been described that the isolation rate is 66.6%. An increase in endotoxin levels in 
patients with advanced cirrhosis has been shown to promote the production of 
multiple pro-inflammatory elements, so the activation of this cytokine cascade in 
spontaneous bacterial peritonitis has been associated with greater complications 
leading to death [60–62].
In recent years the prevalence of Gram-positive bacteria in SBP has increased. 
In addition, there is a growing resistance to multiple drugs such as quinolones, 
which is of particular importance since norfloxacin represents the antimicrobial 
of choice for SBP. But this has changed dramatically, as multidrug resistant 
organisms (MDRO) have been described [63]. A study carried out by Mücke et al.  
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demonstrated that the presence of MDRO and quinolone-resistant Gram-
negative bacteria (QR-GNB) has been associated with the failure of antimicrobial 
prophylaxis [64].
There is great concern worldwide about the increase in antimicrobial resistance, 
which has now been associated with SBP. Appropriate antimicrobial therapy should 
be administered as soon as possible, as inappropriate administration increases 
hospital mortality. Unfortunately, it has been reported that treatment protocols still 
support the use of third-generation cephalosporins as a first line of therapy [65–67]. 
In a meta-analysis carried out by Iogna et al., showed that there is significant uncer-
tainty about the choice of antimicrobial therapy that is best in people with SBP. It 
is important to highlight that the short-term mortality from spontaneous bacterial 
peritonitis (SBP) is high, approximately 25% [68]. Therefore, having the result 
of the culture, and an antimicrobial regimen with a narrower spectrum should be 
started. Based on these findings, it is essential to perform a microbiological surveil-
lance for the use of the correct use of antimicrobials.
3.  Clinical manifestations of spontaneous bacterial peritonitis and 
diagnostic
Patients with liver cirrhosis (LC) and ascites are at a high risk of developing bac-
terial infections, spontaneous bacterial peritonitis [SBP] can be a life-threatening 
infection in these patients [69]. The diagnosis of SBP is based on the patient’s signs 
and symptoms, in addition to the findings at diagnostic paracentesis in a patient 
with ascites fluid. The patient with peritonitis may have symptoms such as abdomi-
nal pain, nausea, vomiting, diarrhea and signs of a systemic inflammatory response 
(hyper or hypothermia, chills, altered white blood cell count, tachycardia, and/or 
Figure 2. 
The role of the gut microbiota in spontaneous bacterial peritonitis. (A) Ecology of the gut microbiota. 
Ecological community in balance of symbiotic microorganisms (anti-inflammatory species) and pathobionts 
(pro-inflammatory species) that share a certain niche and are considered an important factor in health or 
disease. (B) Bacterial translocation in spontaneous bacterial peritonitis. From the intestinal lumen, in a state 
of dysbiosis, bacteria (gram-negative bacilli of enteric origin and to a lesser extent gram-positive) cross the 
intestinal barrier and infect the mesenteric lymph nodes, a process known as bacterial translocation, and 
from there they reach the blood circulation through of the lymphatic pathway leading to the hepatosplenic and 
systemic circulation. Which leads to the development of an inflammatory reaction in the mesenteric lymph 
nodes themselves with the release of pro-inflammatory cytokines. TRL-4 is responsible for the production of 
TNF-α in response to endotoxin, while Th1 cells release interferon γ.
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tachypnea), also presenting with worsening of liver function, hepatic encephalopa-
thy, shock, kidney failure and gastrointestinal bleeding. However, it is important to 
note that SBP can be asymptomatic particularly in outpatients [70].
Diagnostic paracentesis should be performed in all patients who present 
symptoms is extremely important, as the PMN count in the ascitic fluid plays an 
essential role in obtaining a diagnosis of SBP [71]. However, clinical signs and 
symptoms are occasionally absent in patients with SBP [72]. The diagnosis of 
SBP is confirmed based on a PMN count of >250 cells/mm3 in the ascitic fluid 
cell analysis (Figure 3). The cutoff value of 250 PMN cells/mm3 has the greatest 
sensitivity, whereas 500 PMN cells/mm3 exhibits the greatest specificity [73].
The gold standard for ascitic neutrophil count is manual microscopy, but it 
is labor intensive and associated with interobserver variability, time and costs. 
In most places this has been substituted with automated counts based on flow 
cytometry for counting and differentiating cells. This technique has been docu-
mented to have high linearity with manual microscopy and thus sensitivity and 
specificity close to 100% [74].
3.1 Clinical manifestations of spontaneous bacterial peritonitis.
For Spontaneous bacterial peritonitis (SBP) the diagnosis is established based 
on positive ascitic fluid bacterial cultures and the detection of an elevated absolute 
fluid polymorphonuclear neutrophil (PMN) count in the ascites (>250/mm3) with-
out an evident intra-abdominal surgically treatable source of infection (Figure 3). 
In addition, ascitic fluid cultures are negative in approximately 10–60% of patients 
with clinical manifestations of SBP [75].
The Secondary Bacterial Peritonitis, that differs of Spontaneous bacterial 
peritonitis (SBP) consists of ascitic fluid infection due to intraabdominal infections, 
for example, perforation of gastrointestinal tract or abscess. It is much less frequent, 
but has still high mortality rate compared with SBP in patients with LC [76].
Figure 3. 
Recommended empirical antibiotic treatment for SBP. Community-acquired agents are treated with 3rd 
generation Cephalosporins, Amoxicilin/Clavulanic acid, Ciprofloxacin, Ofloxacin or Piperacilin/Tazobactam. 
Health care associated and nosocomial agents are treated with Piperacilin/Tazobactam or a Carbapenem 
antibiotic. For profilaxis of SPB, Norfloxacin is the agent of choice. (Figure adapted from [66]). *In case of 
multidrug resistant organism.
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Non-neutrocytic bacterial ascites or Bacterascites: is an ascitic fluid polymor-
phonuclear -neutrophil (PMN) count below 250/μL and a positive ascitic fluid 
culture results in the absence of an evident intra-abdominal, surgically treatable 
source of infection. It is a different clinical entity than spontaneous bacterial perito-
nitis (SBP), which is characterized by a neutrophil reaction in ascites regardless of 
the bacterial culture result. Bacterascites is prevalent in 8–11% of all patients with 
cirrhosis and ascites, and the clinical significance seems to vary according to how 
the infection was acquired [77].
3.2 Treatment of spontaneous bacterial peritonitis
Even though the spectrum of this chapter does not contemplate treatment 
modalities we thought it best to give an updated brief view of the treatment 
involved in SBP in an easy diagram (Figure 4). First step is to acknowledge and 
apply the indication of a paracentesis, which are the following according to multiple 
clinical practice guidelines: All patients with new onset grade 2 or 3 of ascites, in 
those hospitalized for worsening of ascites or any complication of cirrhosis. Other 
indications are new onset of ascites, any patient admitted to the hospital with 
preexisting ascites, regardless of the reason for admission and ascites who has signs 
of clinical deterioration [78]. Once the diagnosis of SBP is made the treatment 
modalities must be applied as soon as possible (Figure 4). These empiric treatment 
schemes should also be administered if the patient has a diagnosis of culture-
negative neutrocyte ascites and monomicrobial non-neutrocytic bacterial ascites 
or bacterial ascites. Particularly the treatment decision differs from the community 
acquired SBP from the nosocomial one, considering the risk factors, other comor-
bidities treatment and the previous use of antibiotic (3 months at least) to prescribe 
the specific drug, because the microbiome involucrate in each case requires a differ-
ent antibiotic. For example, the use of 3rd. generation cephalosporines in commu-
nity acquired SBP, not such as the treatment suggested in the nosocomial acquired 
SPB that the carbapenem is indicated as first therapeutic option.
Figure 4. 
Diagnostic algorithm of SBP. The diagnosis of SBP is established based on positive ascitic fluid bacterial 
cultures and the detection of an elevated absolute fluid polymorphonuclear neutrophil (PMN) count in the 
ascites (>250/mm3) without an evident intra-abdominal surgically treatable source of infection, except in 
peritonitis associated with peritoneal dialysis, where bacteria can enter the body through the open ends of the 
PD catheter during exchanges.
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The efficacy of antibiotic therapy should ideally be revised doing a second 
paracentesis at 48 hours from the starting treatment. One should suspect either 
resistance to antibiotics, secondary bacterial peritonitis or fungal peritonitis 
if the patient exhibits worsening clinical signs and symptoms or does not have 
a marked reduction in the leucocyte count of at least 25% [78, 79]. In addition 
to the antibiotics administered it is vital to administer albumin 1.5 g/kg body 
weight at diagnosis followed by 1 g/kg on day three. This in order to significantly 
decrease the incidence of type 1 Hepatorenal syndrome and mortality in up to 
30% of the cases [78].
Another important topic is the prophylaxis of SBP in high risk patients which in 
which in summary are three: (1) Patients with acute gastrointestinal hemorrhage; 
(2) Patients with less than 15 g/L of ascitic fluid protein; (3) Patients with previ-
ous history of SBP. For the prophylaxis of SBP in high risk patients the recom-
mended prophylaxis schemes are with norfloxacin [79]. Healthcare providers must 
be very conscious when they are considering the use of prophylactic antibiotics 
balancing the risks of generating gastrointestinal complications secondary to gut 
dysbiosis vs the benefits of preventing an event of SBP. As healthcare workers one 
must avoid the abuse of antibiotic use, it is important to know and apply these 
indications, and imperative to be clear in which antibiotic can be used in these 
specific cases, and avoid the use of broad spectrum antibiotics.
4. Conclusions
In cirrhotic patients, the intestinal barrier dysfunction increased permeability, 
and extensive inflammation occurs due to Spontaneous Bacterial Peritonitis. 
Clinically, the SBP is a frequent and severe complication in cirrhotic patients with 
ascites. It is well documented that bacterial endotoxin and harmful pathogenic 
bacterial species translocate to the liver through portal vein further exacerbate the 
already prevalent hepatic inflammation and fibrosis driven by hepatocytes destruc-
tion and loss of biochemical functionality, thereby these phenomena promote liver 
injury followed by multiorgan failure and eventually death in a high percentage of 
cirrhotic patients.
In this analysis were described that microbiota plays an essential role in this 
pathological process, but it is also related to gut permeability loss due to previous 
treatments or the inflammation sustained signalling by hepatic lesion immuno-
logical response.
Clinically, a flux for diagnostic and treatment was proposed for SBP, that 
includes de analysis of ascitic fluid and polymorphonuclear cells as consequence.
It is suggested that there is a lot of task to do in public health, in order to control 
the self-medication and the excess of antibiotic therapy, in order to avoid micro-
biota dysbiosis and SBP.
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